Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN)

Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario

DYN Maintained by HC Wainwright & Co. -- Price Target Lowered to $32

Piper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)

Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data?

HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Lowers Price Target to $32

Dyne Therapeutics stock rises on positive DM1 trial results

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

After a year, Dyne trial participants showed better walking-test times and muscle strength

Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial

Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?

Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript